BIOV — BioVersys AG Balance Sheet
0.000.00%
Last trade - 00:00- CH₣198.58m
- CH₣215.55m
Annual balance sheet for BioVersys AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | ARS | ARS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Cash | ||
| Cash and Equivalents | ||
| Short Term Investments | ||
| Cash and Short Term Investments | 28.4 | 32.6 |
| Net Total Receivables | 2.06 | 1.29 |
| Prepaid Expenses | ||
| Total Other Current Assets | ||
| Total Current Assets | 33.6 | 34.4 |
| Gross Property, Plant And Equipment | ||
| Accumulated Depreciation | ||
| Net Property, Plant And Equipment | 0.581 | 0.558 |
| Total Assets | 34.2 | 35 |
| Accounts Payable | ||
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Current Portion of Long Term Debt / Capital Leases | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 9.37 | 9.67 |
| Long Term Debt | ||
| Capital Lease Obligations | ||
| Total Long Term Debt | ||
| Total Debt | ||
| Minority Interest | ||
| Total Other Liabilities | ||
| Total Funded Status | ||
| Total Liabilities | 25.6 | 24.3 |
| Common Stock | ||
| Additional Paid In Capital | ||
| Retained Earnings (Accumulated Deficit) | ||
| Other Equity | ||
| Total Equity | 8.58 | 10.7 |
| Total Liabilities & Shareholders' Equity | 34.2 | 35 |
| Total Common Shares Outstanding |